Sika Interplant Systems Ltd
SIKASika Interplant Systems Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting.
The sharpest disagreement: annual EPS moved +43.8% against a −7.6% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (5 weeks in) while the P/E sits at the 94th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −1.0% year on year, and 94% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Sika Interplant Systems Ltd trades at ₹1,115, in a confirmed uptrend and 5 weeks into that stage. That is +10.9% against its own 200-day average. It sits at 59% of a 52-week range of ₹823 to ₹1,316. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks.
Today the stock is in a confirmed uptrend — week 5 of stage 2, confirmed. At ₹1,115 it trades +10.9% versus its 200-day average and sits at 59% of its 52-week range (₹823–₹1,316).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +4,660% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 9 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Sika Interplant Systems Ltd trades at 67.4× P/E, at the pricey end of its own range (94th percentile). Its long-run median P/E is 36.5×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 67.4× is at the pricey end of its own range (94th percentile), against a long-run median of 36.5× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +43.8% against a −7.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +61.5%/yr price move, ~+24.0%/yr came from earnings growth and ~+37.5 pp from the multiple (expanding); over 10y, of the +45.8%/yr price move, ~+36.3%/yr came from earnings growth and ~+9.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Sika Interplant Systems Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +60.5% at its peak to +43.1% but is still expanding, ROCE holding at 34.0%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +42.6% | +52.1% | +21.4% | +17.5% |
| Profit | +44.0% | +58.7% | +24.6% | +33.5% |
| EPS | +43.8% | +60.6% | +25.1% | +35.6% |
| Share price | −7.6% | +96.0% | +61.5% | +45.8% |
4-Factor Sector Score
72.6/100 — rank 2 of 24 in Aerospace & Defence - Equipments · 90% evidence confidence
Sika Interplant Systems Ltd scores 72.6 out of 100 against the 24 companies it is compared with in Aerospace & Defence - Equipments, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 28.4 + 21.9 + 12.9 + 9.4 = 72.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Sika Interplant Systems Ltd reported ₹41.3 Cr of revenue in the Mar 26 quarter, −10.2% year on year. Over 10 years it has compounded at 17.5% a year. The last full year, FY26, came in at ₹211 Cr. The last four reported quarters add to ₹211 Cr.
FY26 revenue came in at ₹211 Cr (+42.6% on the year), capping 10 years at 17.5% compound. The latest quarter (Mar 26) printed ₹41.3 Cr, −10.2% year on year.
Pace check: the last four quarters averaged +50.3% growth against the decade's 17.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +43.1% over the last 4 quarters against +41.1%/yr over the last 8 — stabilising; TTM profit +38.2% vs +37.5%/yr — stabilising.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Sika Interplant Systems Ltd's operating margin is 25.2% in the Mar 26 quarter, +7.9 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 7.0% to 21.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 25.2%, +7.9 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 7.0%–21.0%, and FY26's 21.0% is the top of that band — a record year.
Why the margin moved: operating margin went +7.9 pp year on year while gross margin went +9.3 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Sika Interplant Systems Ltd earned ₹7.8 Cr of net profit in the Mar 26 quarter, −1.0% year on year. Full-year FY26 profit was ₹36.0 Cr. The 10-year compound rate is 33.5%. That is 18.9% of the quarter's revenue. The same quarter a year earlier earned ₹7.9 Cr.
Mar 26 profit was ₹7.8 Cr, −1.0% year on year. On the full year, FY26 printed ₹36.0 Cr (+44.0%), and the 10-year compound rate is 33.5%.
🚨 Why profit moved: revenue contributed −10.2% and the margin +7.9 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +43.3% vs revenue +50.3%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 94% of Sika Interplant Systems Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹47.0 Cr of operating cash against ₹36.0 Cr of profit. After ₹0.0 Cr of capital spending, ₹47.0 Cr was left as free cash.
FY26: operating cash of ₹47.0 Cr against reported profit of ₹36.0 Cr, leaving free cash of ₹47.0 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 94% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 94%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 3.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Sika Interplant Systems Ltd's cash conversion cycle runs 6 days in FY26, up from 4 days in FY21. Capital spending ran ₹11.0 Cr over the last 3 years. At FY26 sales of ₹211 Cr each day of that cycle holds about ₹0.6 Cr, so roughly ₹3.0 Cr sits inside the business at any moment.
FY26: debtors at 18 days, inventory at 3 days — roughly 0.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 6 days, looser than FY21's 4.
The full loop: cash goes out to suppliers and production on day 0; stock waits 3 days to sell; customers pay about 18 days after that; and suppliers themselves are paid at 16 days — netting out to the 6-day cycle.
In money terms: at FY26 sales of ₹211 Cr, each day of the cycle holds about ₹0.6 Cr — so the 6-day loop keeps roughly ₹3.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹11.0 Cr over the last 3 fiscal years against ₹3.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Sika Interplant Systems Ltd earns a ROCE of 35% in FY26. That is up from a trough of 5% in FY18. Return on invested capital clears the cost of that capital by +16.2 percentage points, so growth here adds value rather than only size. The wiring behind it is 17.1% net margin on 1.21× asset turns.
FY26 ROCE is 35%, recovered from a FY18 trough of 5% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 17.1% net margin × 1.21× asset turns × 1.13× balance-sheet leverage ≈ 23.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 28.2% − 12.0% = a +16.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Sika Interplant Systems Ltd carries ₹0.0 Cr of borrowings against ₹155 Cr of equity in FY26, a debt-to-equity of 0.00. Operating profit covers the interest bill 45×. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Capital spending ran ₹11.0 Cr across the last 3 of those years.
FY26: borrowings of ₹0.0 Cr against equity of ₹155 Cr — a debt-to-equity of 0.00. Operating profit covers the interest bill 45×. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr while capital spending ran ₹11.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Sika Interplant Systems Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 71.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +0.5 points over 8 quarters to 3.3%; Promoters: +0.0 points over 8 quarters to 71.7%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Sika Interplant Systems Ltd: the Z-score reads 70.63. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 70.63 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 70.63.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Sigma Advanced System LtdSIGMAADV | 72.6/100Favorable setup93% evidence | LEADER | 24.0/35 Revenue 100% · PAT 100% · OPM change -12 pp 83% evidence | 16.6/25 ROCE 60.8% · OPM 17% 95% evidence | 12.0/20 P/E 42.6× · PEG 2.35 100% evidence | 20.0/20 RS sector 105.2% · RS bench 142.5% · 1Y 494.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24 + 16.6 + 12 + 20 = 72.6 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Sika Interplant Systems Ltdthis pageSIKA | 72.6/100Favorable setup90% evidence | TURNING | 28.4/35 Revenue 43% · PAT 38.1% · OPM change 7.9 pp 88% evidence | 21.9/25 ROCE 34.6% · OPM 25.2% 100% evidence | 12.9/20 P/E 67.4× · PEG 1.01 100% evidence | 9.4/20 RS sector -10.2% · RS bench 6% · 1Y -1.7%3 of 7 weeks ahead 70% evidence |
| Exact sum: 28.4 + 21.9 + 12.9 + 9.4 = 72.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Astra Microwave Products LtdASTRAMICRO | 70.5/100Favorable setup96% evidence | LEADER | 21.0/35 Revenue 10.6% · PAT 27% · OPM change 4 pp 88% evidence | 19.4/25 ROCE 20.2% · OPM 33% 100% evidence | 10.8/20 P/E 91.6× · PEG 1.19 100% evidence | 19.3/20 RS sector 30.4% · RS bench 61.4% · 1Y 90.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 19.4 + 10.8 + 19.3 = 70.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Paras Defence and Space Technologies LtdPARAS | 66.4/100Favorable setup78% evidence | LEADER | 21.8/35 Revenue 30.4% · PAT 43.5% · OPM change -1 pp 83% evidence | 16.8/25 ROCE 16.9% · OPM 25% 76% evidence | 9.2/20 P/E 118× · PEG — 50% evidence | 18.6/20 RS sector 27.1% · RS bench 57.1% · 1Y 60.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 16.8 + 9.2 + 18.6 = 66.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5MTAR Technologies LtdMTARTECH | 63.2/100Mixed-positive evidence90% evidence | FADING | 30.7/35 Revenue 53.5% · PAT 100% · OPM change 6 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 24% 100% evidence | 6.3/20 P/E 129× · PEG — 50% evidence | 12.3/20 RS sector 21.9% · RS bench 44.7% · 1Y 280.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 30.7 + 13.9 + 6.3 + 12.3 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Apollo Micro Systems LtdAPOLLO | 59.9/100Mixed-positive evidence96% evidence | LEADER | 21.9/35 Revenue 60.9% · PAT 92.9% · OPM change 1 pp 88% evidence | 14.2/25 ROCE 14.5% · OPM 23% 100% evidence | 7.1/20 P/E 128× · PEG 1.6 100% evidence | 16.7/20 RS sector 6.5% · RS bench 32% · 1Y 126.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 21.9 + 14.2 + 7.1 + 16.7 = 59.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Vinyas Innovative Technologies LtdVINYAS | 59.3/100Thin evidence · provisional57% evidence | TURNING | 21.7/35 Revenue 65% · PAT 100% · OPM change 3 pp 48% evidence | 18.5/25 ROCE 21.4% · OPM 13% 95% evidence | 10.9/20 P/E 51.1× · PEG — 15% evidence | 8.2/20 RS sector -17.5% · RS bench 6% · 1Y -6.9%10 of 11 weeks ahead 70% evidence |
| Exact sum: 21.7 + 18.5 + 10.9 + 8.2 = 59.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Data Patterns (India) LtdDATAPATTNS | 58.1/100Mixed-positive evidence100% evidence | FADING | 21.5/35 Revenue 33.9% · PAT 24.2% · OPM change -5 pp 100% evidence | 18.6/25 ROCE 21.9% · OPM 27% 100% evidence | 5.0/20 P/E 88.7× · PEG 3.94 100% evidence | 13.0/20 RS sector 5% · RS bench 30.1% · 1Y 59.9%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 18.6 + 5 + 13 = 58.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 9Azad Engineering LtdAZAD | 57.4/100Mixed-positive evidence89% evidence | FADING | 24.5/35 Revenue 32.2% · PAT 54% · OPM change 2 pp 88% evidence | 12.9/25 ROCE 11.9% · OPM 38% 100% evidence | 8.0/20 P/E 111× · PEG 2.29 65% evidence | 12.0/20 RS sector 1.6% · RS bench 27% · 1Y 47.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 12.9 + 8 + 12 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Ideaforge Technology LtdIDEAFORGE | 57.1/100Mixed-positive evidence68% evidence | LEADER | 24.6/35 Revenue 41% · PAT 71.4% · OPM change 152 pp 65% evidence | 4.6/25 ROCE -2.8% · OPM 44% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 17.9/20 RS sector 25.6% · RS bench 53.6% · 1Y 85.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.6 + 4.6 + 10 + 17.9 = 57.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Hindustan Aeronautics LtdHAL | 56.2/100Mixed-positive evidence96% evidence | BREAKING OUT | 11.0/35 Revenue 6.8% · PAT 9% · OPM change -3 pp 88% evidence | 21.1/25 ROCE 32% · OPM 36% 100% evidence | 15.2/20 P/E 34.1× · PEG 1.18 100% evidence | 8.9/20 RS sector -18.6% · RS bench 4% · 1Y 2.1%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 21.1 + 15.2 + 8.9 = 56.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Rossell Techsys LtdROSSTECH | 54.1/100Mixed-positive evidence83% evidence | FADING | 29.0/35 Revenue 82.9% · PAT 68.8% · OPM change 1.8 pp 100% evidence | 7.4/25 ROCE 11.5% · OPM 14.4% 100% evidence | 9.0/20 P/E 136× · PEG — 15% evidence | 8.7/20 RS sector -3.2% · RS bench 20.7% · 1Y 64.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 7.4 + 9 + 8.7 = 54.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jaykay Enterprises LtdJAYKAY | 49.0/100Mixed-negative evidence62% evidence | ASLEEP | 25.8/35 Revenue 100% · PAT 100% · OPM change 34 pp 62% evidence | 6.8/25 ROCE 8.2% · OPM -10% 95% evidence | 11.5/20 P/E 32.6× · PEG — 15% evidence | 4.9/20 RS sector -20.9% · RS bench -6.2% · 1Y 20.6%6 of 10 weeks ahead 70% evidence |
| Exact sum: 25.8 + 6.8 + 11.5 + 4.9 = 49 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -20.9% and the one-year return is 20.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 14Mishra Dhatu Nigam LtdMIDHANI | 45.7/100Mixed-negative evidence96% evidence | FADING | 16.3/35 Revenue 12.6% · PAT 18.9% · OPM change -2 pp 88% evidence | 13.7/25 ROCE 11.3% · OPM 21% 100% evidence | 7.4/20 P/E 56.4× · PEG 5.62 100% evidence | 8.3/20 RS sector -16.9% · RS bench 5.1% · 1Y -2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 13.7 + 7.4 + 8.3 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Dynamatic Technologies LtdDYNAMATECH | 43.8/100Mixed-negative evidence89% evidence | FADING | 16.2/35 Revenue 15.5% · PAT -23.3% · OPM change 1 pp 88% evidence | 10.2/25 ROCE 10% · OPM 11% 100% evidence | 10.3/20 P/E 140× · PEG 1.42 65% evidence | 7.1/20 RS sector -12.3% · RS bench 10.4% · 1Y 47.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 10.2 + 10.3 + 7.1 = 43.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Zen Technologies LtdZENTEC | 41.9/100Mixed-negative evidence69% evidence | ASLEEP | 5.0/35 Revenue -23.4% · PAT -27.8% · OPM change -14 pp 95% evidence | 16.6/25 ROCE 16.2% · OPM 27% 76% evidence | 10.5/20 P/E 80.7× · PEG — 15% evidence | 9.8/20 RS sector -6.5% · RS bench 6.5% · 1Y -8.7%8 of 10 weeks ahead 70% evidence |
| Exact sum: 5 + 16.6 + 10.5 + 9.8 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Bharat Electronics LtdBEL | 41.7/100Mixed-negative evidence100% evidence | ASLEEP | 14.0/35 Revenue 19.8% · PAT 11.8% · OPM change -3 pp 100% evidence | 18.6/25 ROCE 36.5% · OPM 25% 100% evidence | 7.3/20 P/E 46.1× · PEG 3.54 100% evidence | 1.8/20 RS sector -28% · RS bench -8% · 1Y -1.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 18.6 + 7.3 + 1.8 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Aequs LtdAEQUS | 36.4/100Thin evidence · provisional51% evidence | BREAKING OUT | 15.1/35 Revenue 44.3% · PAT — · OPM change -7.3 pp 74% evidence | 1.3/25 ROCE 1.6% · OPM 3.7% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 15.1 + 1.3 + 10 + 10 = 36.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Avantel LtdAVANTEL | 35.7/100Mixed-negative evidence77% evidence | TURNING | 10.1/35 Revenue -3.2% · PAT -67.2% · OPM change 4.6 pp 100% evidence | 9.2/25 ROCE 9.6% · OPM 24.8% 100% evidence | 8.7/20 P/E 251× · PEG — 15% evidence | 7.7/20 RS sector -11.9% · RS bench 0.1% · 1Y 19%8 of 11 weeks ahead 70% evidence |
| Exact sum: 10.1 + 9.2 + 8.7 + 7.7 = 35.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20AXISCADES Technologies LtdAXISCADES | 35.4/100Mixed-negative evidence96% evidence | ASLEEP | 15.4/35 Revenue 12.4% · PAT -4.3% · OPM change -1.7 pp 88% evidence | 12.3/25 ROCE 15.3% · OPM 12.3% 100% evidence | 4.9/20 P/E 83.6× · PEG 3.04 100% evidence | 2.8/20 RS sector -21.3% · RS bench -1.3% · 1Y 13.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 12.3 + 4.9 + 2.8 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21NIBE LtdNIBE | 32.4/100Adverse evidence65% evidence | TURNING | 9.6/35 Revenue -6.7% · PAT -80% · OPM change 3 pp 83% evidence | 7.6/25 ROCE 4.8% · OPM 20% 76% evidence | 8.5/20 P/E 380× · PEG — 15% evidence | 6.7/20 RS sector -29.8% · RS bench 11.1% · 1Y -17%11 of 11 weeks ahead 70% evidence |
| Exact sum: 9.6 + 7.6 + 8.5 + 6.7 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Bharat Dynamics LtdBDL | 29.4/100Adverse evidence83% evidence | ASLEEP | 7.6/35 Revenue -27% · PAT -23.6% · OPM change -5 pp 88% evidence | 12.9/25 ROCE 13.8% · OPM 12% 100% evidence | 5.0/20 P/E 109× · PEG 4.44 65% evidence | 3.9/20 RS sector -22.4% · RS bench -11.8% · 1Y -24.4%2 of 10 weeks ahead 70% evidence |
| Exact sum: 7.6 + 12.9 + 5 + 3.9 = 29.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23BEML LtdBEML | 26.3/100Adverse evidence90% evidence | ASLEEP | 6.5/35 Revenue 8.1% · PAT -51.5% · OPM change -11 pp 88% evidence | 5.3/25 ROCE 7.7% · OPM 15% 100% evidence | 9.5/20 P/E 103× · PEG 1.18 100% evidence | 5.0/20 RS sector -19.9% · RS bench -6.2% · 1Y -15.6%5 of 10 weeks ahead 70% evidence |
| Exact sum: 6.5 + 5.3 + 9.5 + 5 = 26.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24DCX Systems LtdDCXINDIA | 25.1/100Adverse evidence67% evidence | ASLEEP | 8.2/35 Revenue -31.4% · PAT -80% · OPM change -2 pp 83% evidence | 3.4/25 ROCE 0.9% · OPM -0.2% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.5/20 RS sector -27% · RS bench -12.4% · 1Y -32%5 of 10 weeks ahead 70% evidence |
| Exact sum: 8.2 + 3.4 + 10 + 3.5 = 25.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Sika Interplant Systems Ltd's share price today?
Sika Interplant Systems Ltd trades at ₹1,115, −7.6% over the past year. The company is valued at ₹2,365 Cr. The stock sits at 59% of its 52-week range of ₹823–₹1,316, +10.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 5 weeks in. — as of 31 July 2026.
What were Sika Interplant Systems Ltd's latest quarterly results?
Sika Interplant Systems Ltd reported revenue of ₹41.3 Cr and net profit of ₹7.8 Cr for the Mar 26 quarter. Revenue fell 10.2% and profit fell 1.0% year on year. Earnings per share were ₹3.69. The operating margin was 25.2%, 7.9 pp higher than a year earlier. — as of 31 July 2026.
What is Sika Interplant Systems Ltd's revenue?
Sika Interplant Systems Ltd reported revenue of ₹41.3 Cr in the Mar 26 quarter, −10.2% year on year. For the full FY26 fiscal year, revenue was ₹211 Cr (+42.6%). Over the last 10 years revenue compounded at 17.5% a year. — as of 31 July 2026.
What is Sika Interplant Systems Ltd's profit?
Sika Interplant Systems Ltd earned ₹7.8 Cr of net profit in the Mar 26 quarter, −1.0% year on year. Full-year FY26 profit was ₹36.0 Cr. The operating margin ran 25.2% in the latest quarter. — as of 31 July 2026.
What is Sika Interplant Systems Ltd's market cap?
Sika Interplant Systems Ltd's market capitalisation is ₹2,365 Cr at a share price of ₹1,115. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Sika Interplant Systems Ltd's P/E ratio?
Sika Interplant Systems Ltd trades at a P/E of 67.4×, at the 94th percentile of its own 10-year range, against a long-run median of 36.5×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Sika Interplant Systems Ltd pay a dividend?
Yes — Sika Interplant Systems Ltd's dividend payout was 20% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is Sika Interplant Systems Ltd overvalued?
On its own history, Sika Interplant Systems Ltd looks expensive against its own history: its P/E of 67.4× sits at the 94th percentile of its 10-year range (long-run median 36.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is Sika Interplant Systems Ltd growing?
Not right now — Sika Interplant Systems Ltd's latest numbers are shrinking: latest-quarter revenue −10.2% year on year, profit −1.0%, and the margin +7.9 pp at 25.2%. The 10-year compound rates are 17.5% (revenue) and 33.5% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is Sika Interplant Systems Ltd performing?
Sika Interplant Systems Ltd is in a confirmed uptrend, 5 weeks in. Its latest quarter's revenue fell 10.2% and profit fell 1.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 9 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is Sika Interplant Systems Ltd in?
Mixed — growth is normalizing off a hyper-growth base: revenue growth has eased from +60.5% at its peak to +43.1% but is still expanding, ROCE holding at 34.0%. The read comes from the last 12 quarters of growth (revenue growth +43.1% latest, profit growth +38.2% latest, eps growth +38.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Sika Interplant Systems Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 5 of stage 2), trading +10.9% versus its 200-day average and at 59% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Sika Interplant Systems Ltd beating the market?
On recent form, yes — Sika Interplant Systems Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 9 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +4,660% against the NIFTY 500's +276% — ahead of the index over the full window. — as of 31 July 2026.
Will Sika Interplant Systems Ltd's share price go up?
This page publishes no price forecast for Sika Interplant Systems Ltd. What it measures instead: the share price is ₹1,115, the price is in a confirmed uptrend 5 weeks in. Its P/E of 67.4× sits at the 94th percentile of its own 10-year range. — as of 31 July 2026.
Who owns Sika Interplant Systems Ltd?
Promoters hold 71.7% of Sika Interplant Systems Ltd, foreign institutions 3.3%, domestic institutions 0.0% and the public 25.0% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 31 July 2026.
Does Sika Interplant Systems Ltd have too much debt?
No — Sika Interplant Systems Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill 45×. FY26 borrowings were ₹0.0 Cr against equity of ₹155 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Sika Interplant Systems Ltd's capex?
Sika Interplant Systems Ltd spent ₹11.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹0.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is Sika Interplant Systems Ltd's cash flow?
Sika Interplant Systems Ltd generated ₹47.0 Cr of operating cash flow in FY26 and ₹47.0 Cr of free cash flow after ₹0.0 Cr of capital spending. Reported profit that year was ₹36.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Sika Interplant Systems Ltd's profit real cash?
Yes — over the last 3 fiscal years, 94% of Sika Interplant Systems Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹47.0 Cr against reported profit of ₹36.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
How financially safe is Sika Interplant Systems Ltd?
On the balance sheet, the Z-score reads 70.63 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 31 July 2026.
Where is Sika Interplant Systems Ltd in its business cycle?
Sika Interplant Systems Ltd's FY26 operating margin was 21.0%, against a 13-year band of 7.0%–21.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 25.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Sika Interplant Systems Ltd story?
The sharpest disagreement: annual EPS moved +43.8% against a −7.6% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Sika Interplant Systems Ltd a stock worth studying right now?
This is not investment advice. The machine read: Sika Interplant Systems Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.